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Abstract
Purpose Themain purpose of this study was to investigate the
effects of a 12-week, clinician-referred, community-based ex-
ercise training program with supervised and unsupervised ses-
sions for men with prostate cancer. The secondary purpose
was to determine whether androgen deprivation therapy
(ADT) modified responses to exercise training.
Methods Secondary analysis was undertaken on data from a
multicentre cluster randomised controlled trial in which 15
clinicians were randomly assigned to refer eligible patients
to an exercise training intervention (n=8) or to provide usual
care (n=7). Data from 119 patients (intervention n=53, con-
trol n=66) were available for this analysis. Outcomemeasures
included fitness and physical function, anthropometrics, rest-
ing heart rate, and blood pressure.
Results Compared to the control condition, men in the inter-
vention significantly improved their 6-min walk distance
(Mdiff =49.98 m, padj =0.001), leg strength (Mdiff =21.82 kg, p-
adj =0.001), chest strength (Mdiff =6.91 kg, padj =0.001), 30-s
sit-to-stand result (Mdiff = 3.38 reps, padj = 0.001), and reach
distance (Mdiff =4.8 cm, padj =0.024). A significant difference
(unadjusted for multiplicity) in favour of men in the interven-
tion was also found for resting heart rate (Mdiff =−3.76 beats/
min, p=0.034). ADT did not modify responses to exercise
training.
Conclusions Men with prostate cancer who act upon clinician
referrals to community-based exercise training programs can
improve their strength, physical functioning, and, potentially,
cardiovascular health, irrespective of whether or not they are
treated with ADT.
Implications for Cancer Survivors Clinicians should inform
men with prostate cancer about the benefits of exercise and
refer them to appropriately qualified exercise practitioners and
suitable community-based programs.
Trial registration Australia and New Zealand Clinical Trials
Register (ANZCTR): ACTRN12610000609055
Keywords Prostate cancer . Androgen deprivation therapy .
Aerobic exercise training . Resistance exercise training .
Fitness . Physical function
Introduction
Prostate cancer is the most frequently diagnosed cancer
among men in more developed regions of the world [1],
with the trend in 5-year relative survival rates approaching
100 % in some counties [2–4]. Men with prostate cancer
typically experience adverse effects associated with the dis-
ease and its treatment, however, including urinary leakage,
bowel urgency, erectile dysfunction [5], fatigue [6], anxiety
and depression [7], and diminished health-related quality of
life [8]. In addition, those treated with androgen deprivation
therapy (ADT) are at increased risk of bone fracture, muscle
mass and strength loss, diabetes, obesity, and cardiovascular-
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related mortality [9, 10]. With this profile of adverse effects,
counselling men with prostate cancer to engage in exercise
training, in combination with other health promoting activi-
ties, has been recommended [11].
Exercise training can improve the health and well-
being of men with prostate cancer, including aerobic fit-
ness, muscular performance (endurance and strength), fa-
tigue, flexibility, body composition (lean body mass),
blood lipids, and quality of life [12–14]. The evidence is
less clear, however, on the effects of exercise training on
other parameters, such as blood pressure [15–17]. In ad-
dition, greater clarity is needed with regard to whether
responses to exercise training differ between men with
prostate cancer receiving ADT and those not receiving
this treatment. Studies conducted thus far have shown
minimal differences between these two cohorts [18, 19].
Given the potential of exercise training to reduce the se-
verity of many of the adverse effects of ADT [10], iden-
tifying differences between these two cohorts in their re-
sponses to exercise training would inform the design of
more effective programs.
One of the features of previous studies involving exer-
cise training and prostate cancer is that trials have been
conducted using supervised (i.e. in the presence of a ther-
apist or exercise physiologist) or unsupervised (e.g. home-
based without a therapist or exercise physiologist) pro-
grams [13, 14]. Demonstrating the effectiveness of a com-
bined program has value, as men with prostate cancer are
likely to have opportunities to undertake supervised and
unsupervised exercise training in their communities (e.g.
gyms that offer supervised classes and unstructured, self-
initiated training). There seems to be merit in continuing
this line of enquiry through designing interventions with
features that replicate circumstances that men with pros-
tate cancer are likely to experience.
With exercise training emerging as a key intervention
for improving the lives of men with prostate cancer [20],
we sought to clarify its effects further in community set-
tings. We report findings from a cluster randomised con-
trolled trial of exercise training for men with prostate can-
cer. This trial had several features that enhanced the eco-
logical validity of the intervention: (a) clinicians referred
men with prostate cancer to the exercise training program,
(b) the program involved both supervised training and
unsupervised home-based sessions, and (c) the supervised
sessions were conducted in community gyms. The prima-
ry aim of the study was to investigate the effects of the
12-week exercise training program on fitness and physical
function, anthropometric measurements, resting heart rate,
and blood pressure. The secondary aim was to determine
whether the effects of the program, in terms of exercise
outcomes, were different for men who received and those
who had not received ADT.
Method
Design
This study represents planned secondary analysis of data from
a multicentre, cluster randomised controlled trial to determine
the efficacy of a clinician referral and 12-week exercise train-
ing program for improving exercise levels and quality of life
for men with prostate cancer. A detailed description of the
study methods is available from the published protocol [21]
and the main outcomes have been published [22]. In brief, 15
clinicians were randomised to intervention and control condi-
tions. During consultations, clinicians in both conditions de-
termined each patient’s eligibility to participate in the trial.
Using short pre-prepared scripts, clinicians recommended el-
igible patients participate in the trial and advised ineligible
patients not to participate [21]. Clinicians in the intervention
condition (n=8) referred eligible patients to an exercise train-
ing program involving two supervised sessions in community
gyms and one unsupervised home-based session per week.
Clinicians referred patients using a standardised referral slip,
which reiterated the recommendation to participate in the ex-
ercise training program. Clinicians in the control condition
(n=7) recommended eligible patients participate in the trial
and provided usual care regarding advice on exercise training
(typically, limited amounts of information are provided).
Clinician adherence to the referral process was monitored
weekly with emails and personal contact with clinicians at
the clinics, checking that they were following the protocol
and answering any queries that they may have had. The pa-
tients in both conditions completed measures associated with
the primary outcomes of the main study [22], and were also
invited to take part in measurements of their fitness and phys-
ical function, anthropometrics, resting heart rate, and blood
pressure. Assessments were conducted before the exercise
training program begun (baseline) and following the program
(12 weeks).
The protocol for this study received approval from the hu-
man research ethics committee of the host university and those
of the healthcare services involved with participant recruit-
ment. Each participant provided written informed consent.
Participants
The 15 clinicians involved in this study practised at urology
and radiation oncology outpatient clinics across three major
public health services and four private clinics in Melbourne,
Australia. Their patients (n=741) were screened to determine
their eligibility for this study (see Table 1).
Sample size calculations were based on the primary out-
come of the main study (self-reported involvement in
moderate and strenuous physical activity) [21, 22], rather than
the secondary analysis reported here.
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Exercise training intervention
The 12-week exercise training program involved each partic-
ipant undertaking two supervised, 50-min sessions at their
local community gym and one other home-based session per
week. Under the supervision of accredited exercise physiolo-
gists (tertiary-educated exercise professionals), postgraduate
exercise physiology students from two universities (in training
to become accredited exercise physiologists) supervised par-
ticipants during their gym sessions and provided advice and
written instruction for their home-based sessions. The exercise
training programs were based on exercise training guidelines
for cancer survivors from the American College of Sports
Medicine [23] and Exercise and Sport Science Australia [24].
The supervising accredited exercise physiologists have ex-
tensive training and experience working with clinical popula-
tions, including those with cardiovascular disease, diabetes,
cancer, arthritis, and chronic kidney disease. The Masters-
level students, as part of their regular coursework, received
education on exercise prescription for people with cancer, as
well as on working with various comorbidities that may be
present in this clinical population. Prior to training participants
in this study, students also received an induction from the
supervising accredited exercise physiologists, during which
prescription guidelines and training expectations for men with
prostate cancer were discussed.
Supervised sessions were performed at community gyms
(six YMCA centres and one university-based gym) across
Melbourne. The YMCA centres and university-based gym
represent accessible and affordable community gyms. For
convenience, participants trained at the community gyms lo-
cated closest to them. Each supervised session included 20–
30 min of aerobic training, prescribed at 40–70 % of maxi-
mum heart rate, and 4–6 upper and lower body resistance
training exercises, prescribed as two sets of 8–12 repetitions.
To achieve consistency in exercise prescription, each partici-
pant’s program included a 90° leg press, seated chest press,
and seated row. The home-based exercise training programs
included both aerobic and resistance exercises, with body
weight and resistance-band exercises prescribed to increase
the range of exercises participants could perform
independently at home. Programs were frequently modified
and safely progressed to ensure continual fitness gains.
Outcome measures
Fitness and physical function Participants completed five
functional exercise tests that are common and safe for cancer
survivors [25]. Aerobic fitness was assessed using the 6-min
walk test [26]. Upper and lower body maximal strength was
measured using a one-repetition maximum protocol [25] with
the 90° leg press and seated chest press. Lower bodymuscular
endurance was assessed using the 30-s sit-to-stand test [27].
Balance was assessed using the functional reach test [28].
Anthropometrics Height and body mass were measured
using a portable stadiometer (220, Seca, Hamburg,
Germany) and portable scales (UC-321, A&D, Tokyo,
Japan), respectively. Body mass index (BMI) was then calcu-
lated. Girth measurements of the chest, waist, hips, upper arm,
and mid-thigh were taken using standard techniques [29].
Resting heart rate and blood pressureAssessment of resting
heart rate (Electro N2965, Polar, Kempele, Finland) and blood
pressure (Gamma 4.0 sphygmomanometer, Heine, Herrsching,
Germany) were obtained manually. Both measures were taken
after each participant had been seated for 10 min.
Statistical analyses
Data were analysed using SAS software, version 9.3 (SAS
Institute, Cary, NC). The baseline characteristics of partici-
pants in the intervention and control conditions were com-
pared using chi-squared and Fisher’s exact tests for categorical
variables (relationship status, highest level of education, stage
of disease, treatment regime, ADT, and health service type)
and linear mixed models (LMM) with intervention as a fixed
effect and clinician as a random effect for continuous variables
(age, weeks since active treatment, fitness and physical func-
tion, anthropometrics, resting heart rate, and blood pressure).
All LMM analyses conducted in this study included clinician
as a random effect to account for the clustering due to
randomisation at the clinician level.
The effect of the intervention on changes in fitness and
physical function, anthropometrics, resting heart rate, and
blood pressure between baseline and end of follow-up was
determined using LMM with clinician as a random effect.
For this analysis, missing data at 12 weeks were imputed
using the Markov chain Monte Carlo algorithm with 20 im-
putations [30].
To evaluate effect modification of the intervention due to
ADT, LMMwere fitted with intervention, ADT, and the inter-
action term, intervention×ADT, as fixed effects and clinician
as a random effect.
Table 1 Study inclusion and exclusion criteria
Inclusion criteria
Diagnosed with stage I, II, or III prostate cancer
Completed active treatment for prostate cancer within the previous
3–12 months (patients on hormone treatment were eligible to
participate)
The ability to complete surveys in the English language
Exclusion criteria
Any musculoskeletal, cardiovascular, or neurological disorders that
could limit exercising
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Due to the effect of multiple comparisons on experiment-
wise error (multiplicity), adjusted p values were calculated for
the 16 tests included in the primary analysis. Both adjusted
and unadjusted p values are reported for these tests. Adjusted
p values were computed using Hommel’s [31] procedure,
which has been shown to have superior statistical power to
the original Bonferroni procedure and similar power to other
alternatives [32].
Results
Baseline participant characteristics, attrition, compliance
with the intervention, and safety
Of those screened, 147 patients were eligible and agreed to
participate in the main study, with 54 referred from clini-
cians randomised to the intervention condition and 93 re-
ferred from clinicians in the control condition [22]. Of these
147 men, 119 participants (intervention n = 53, control
n=66) provided data for this secondary analysis. One man
withdrew from the intervention condition before baseline
data were collected for this secondary analysis, and 27
men from the control condition gave their consent to partic-
ipate in the main study on the proviso that they did not have
to provide physiological data for this secondary analysis.
Compared to men who did not provide physiological data,
those who did participate in data collection for this second-
ary analysis were 4.2 years older (p=0.036) and had under-
gone different treatment regimens (more likely to have had
surgery and radiotherapy [24.2 vs 0.0 %] or radiotherapy
and ADT [12.1 vs 0.0 %], and less likely to have had sur-
gery only [43.9 vs 63.0 %], radiotherapy only [16.7 vs
18.5 %], surgery, radiotherapy, and ADT [3.0 vs 11.1 %],
or surgery and ADT [0.0 vs 7.4 %], p=0.0006). In addition,
4.5 weeks more had elapsed since active treatment for the
men who participated in the data collection (p=0.032).
No significant differences between the intervention and
control conditions were observed for any participant charac-
teristic (see Table 2). Of the 119 participants, 11 men (inter-
vention n=6, control n=5) withdrew or were lost to follow-
up (refer to main study paper for details [22]). In comparison
to those who underwent assessment at 12 weeks, those who
did not attend this assessment had larger chests and waists, as
well as higher diastolic blood pressure at baseline (p<0.05 for
all). No other statistically significant differences were found.
Comparisons of the non-attendees from the intervention
(n=6) and control (n=5) conditions yielded no statistically
significant differences (the power to detect such differences
was low, however).
At baseline, compared with men not receiving ADT, those
receiving ADT were older (Mdiff = 7.3 years, 95 % CI [3.4,
11.2], p < 0.0001), had higher systolic blood pressure
(Mdiff = 8.4 mmHg, 95 % CI [1.6, 15.2], p=0.016), walked
less distance over 6 min (Mdiff =−44.5 m, 95 % CI [−83.8,
−5.2] , p = 0.027) , and had lower ches t s t rength
(Mdiff =−13.6 kg, 95 % CI [−25.2, −2.0], p=0.022) and leg
strength (Mdiff = −43.4 kg, 95 % CI [−68.1, −18.8],
p=0.0007). In addition, for men receiving ADT, more time
had elapsed since active treatment (Mdiff = 5.9 weeks, 95 % CI
[0.5, 11.3], p=0.034).
As has been reported previously, 85 % of the men in the
intervention condition undertook at least 18 of the 24 super-
vised sessions in their local community gyms and, of those
who completed their exercise diaries (74 %), 81 % completed
at least 9 of 12 home-based sessions [22].
Adverse events (musculoskeletal injuries) were reported
for two participants. One man in the intervention condition
aggravated a previous rotator cuff injury (left shoulder, grade
I strain) during exercise training. The other man, in the control
condition, aggravated a previous meniscus injury (right knee,
inflammation) during baseline testing.
Fitness and physical function
Sizable, statistically significant differences between condi-
tions were observed, in favour of men in the intervention
condition for all measures of physical functioning (Table 3).
Examinations of the possible modifying effect of ADT
treatment on the intervention effect revealed minimal, non-
significant differences between men receiving ADTand those
not receiving this treatment. The mean intervention effects
were similar for 6-min walk distance (ADT 59.7 m, 95 % CI
[11.8, 107.5]; non-ADT 47.5 m, 95 % CI [21.8, 73.2];
p=0.673), leg strength (ADT 13.7 kg, 95 % CI [−8.4, 35.8];
non-ADT 25.2 kg, 95 % CI [13.9, 36.5]; p=0.370), chest
strength (ADT 8.5 kg, 95 % CI [−0.7, 17.7]; non-ADT
7.1 kg, 95 % CI [2.7, 11.4]; p=0.788), 30-s sit-to-stand result
(ADT 4.0 reps, 95%CI [0.4, 7.6]; non-ADT 3.4 reps, 95%CI
[1.5, 5.2]; p=0.778), and reach distance (ADT 7.1 cm, 95 %
CI [−0.1, 14.4]; non-ADT 4.1 cm, 95 % CI [0.5, 7.7];
p=0.487).
Anthropometrics
Differences between conditions were minimal and none were
statistically significant (Table 3). Changes over time were also
minimal, with the only statistically significant result (unadjusted
p only) being a 1.65-cm mean average reduction in hip circum-
ference in favour of the men in the intervention condition.
Resting heart rate and blood pressure
The resting heart rates of the men in the intervention condition
decreased by 3.76 beats/min more than those of men in the
control condition (see Table 3).
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Table 2 Baseline participant
characteristics Characteristics Intervention (n= 53) Control (n = 66) p
a
Mean ± SD
or n (%)
Mean± SD
or n (%)
Demographic characteristics
Age (years) 66.8 ± 8.3 66.0 ± 8.1 0.276
Relationship status 0.809
Married 41 (78.8) 47 (73.4)
De facto or living with partner 3 (5.8) 6 (9.4)
Separated, divorced, widowed,
or not living with partner
8 (15.4) 11 (17.2)
Highest level of education 0.974
Primary school 3 (5.8) 4 (6.3)
Secondary school 15 (28.8) 17 (27.0)
Certificate or diploma 18 (34.6) 24 (38.1)
University degree 16 (30.8) 18 (28.6)
Clinical characteristics
Stage of disease 0.075
Stage I 19 (46.3) 22 (36.7)
Stage II 11 (26.8) 29 (48.3)
Stage III 11 (26.8) 9 (15.0)
Treatment regime 0.347
Surgery only 18 (34.0) 29 (43.9)
Radiotherapy only 5 (9.4) 11 (16.7)
Surgery and radiotherapy 15 (28.3) 16 (24.2)
Radiotherapy and androgen
deprivation therapy
12 (22.6) 8 (12.1)
Surgery, radiotherapy,
and androgen deprivation therapy
3 (5.7) 2 (3.0)
Androgen deprivation therapy
No 38 (71.7) 56 (84.8) 0.112
Yes 15 (28.3) 10 (15.2)
Weeks since active treatment 25.3 ± 11.4 26.5 ± 9.4 0.586
Health service type
Public 39 (73.6) 50 (75.8) 0.834
Private 14 (26.4) 16 (24.2)
Physical function
6-min walk distance (m) 543.7 ± 81.8 551.7 ± 67.9 0.793
Leg—1 repetition maximum (kg) 126.1 ± 46.0 136.8 ± 42.7 0.181
Chest—1 repetition maximum (kg) 60.5 ± 22.8 60.0 ± 21.6 0.540
30-s sit-to-stand (n) 14.2 ± 3.6 14.8 ± 4.1 0.395
Reach distance (cm) 36.4 ± 5.8 38.2 ± 7.8 0.331
Anthropometrics
Body mass index (kg/m2) 28.5 ± 3.7 28.9 ± 4.0 0.510
Chest circumference (cm) 101.9 ± 7.7 102.4 ± 8.3 1.000
Waist circumference (cm) 97.7 ± 9.9 98.3 ± 10.6 0.693
Hip circumference (cm) 102.2 ± 6.5 103.1 ± 7.7 0.671
Right thigh circumference (cm) 47.9 ± 4.4 49.0 ± 4.7 0.365
Left thigh circumference (cm) 47.9 ± 4.2 48.6 ± 4.5 0.490
Right arm circumference (cm) 30.5 ± 2.9 30.8 ± 3.1 0.723
Left arm circumference (cm) 30.1 ± 3.2 30.5 ± 3.1 0.583
Resting heart rate and blood pressure
Resting heart rate (beats/min) 71.2 ± 10.9 72.0 ± 13.3 0.444
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Discussion
This trial demonstrates that the fitness and physical function-
ing of men with prostate cancer can be enhanced through an
exercise training program with features that many men could
encounter during their clinical care and within their commu-
nities. The intervention commenced with the referral of men
with prostate cancer to an exercise training program—an ini-
tiative that is consistent with guidelines recommending clini-
cians counsel prostate cancer survivors to engage in at least
150 min of physical activity per week [11]. At present, no
direct formalised pathway exists between oncology clinicians
and allied health providers in Australia. People with chronic
conditions and complex care needs (including people with
cancer), however, may each be eligible for Medicare rebates
for up to five allied health consultations per calendar year
(including with accredited exercise physiologists [33])
through referrals from general practitioners. Enabling direct
referrals between oncology clinicians and allied health profes-
sionals, such as exercise physiologists, would facilitate earlier
intervention and improve access to exercise training programs
for men with prostate cancer. The combination of supervised
and unsupervised sessions also matches the reality that most
men will be able to access practical support for their physical
activity participation from their local communities.
Community gyms (and many commercial ones), for example,
typically assist members through writing exercise programs
for them, providing periodic program reviews, having staff
available to demonstrate correct exercise techniques, and run-
ning group exercise classes. In addition, YMCA Australia
Table 2 (continued)
Characteristics Intervention (n= 53) Control (n = 66) pa
Mean ± SD
or n (%)
Mean± SD
or n (%)
Systolic blood pressure (mmHg) 134.6 ± 11.5 136.6 (11.9) 0.942
Diastolic blood pressure (mmHg) 83.1 ± 8.5 84.5 ± 8.2 0.448
a Fisher’s exact test for categorical variables, linear mixed model including intervention as fixed effect and
clinician as random effect for continuous variables. No adjustments were made for multiplicity
Table 3 Changes in fitness and physical function, anthropometrics, resting heart rate, and blood pressure, and from baseline to 12 weeks: comparison
between conditions
Variable Mean change (95 % CI) Mean intervention effect (95 % CI)
Intervention (n= 53) Control (n= 66) Intervention—control pa padj
b
Fitness and physical function
6-min walk distance (m) 64.87 (49.76, 79.99) 14.89 (0.47, 29.31) 49.98 (28.54, 71.42) <0.0001 0.001
Leg—1 repetition maximum (kg) 28.54 (21.54, 35.54) 6.72 (−0.06, 13.49) 21.82 (12.15, 31.49) <0.0001 0.001
Chest—1 repetition maximum (kg) 10.05 (7.30, 12.80) 3.14 (0.59, 5.69) 6.91 (3.31, 10.51) <0.0001 0.001
30-s sit-to-stand (reps) 3.89 (2.80, 4.99) 0.51 (−0.54, 1.56) 3.38 (1.87, 4.89) <0.0001 0.001
Reach distance (cm) 3.17 (0.92, 5.41) −1.63 (−3.71, 0.45) 4.80 (1.77, 7.82) 0.002 0.024
Anthropometrics
Body mass index (kg/m2) −0.02 (−0.24, 0.20) 0.05 (−0.15, 0.24) −0.07 (−0.36, 0.23) 0.654 0.788
Chest circumference (cm) −0.75 (−1.66, 0.16) −0.01 (−0.82, 0.79) −0.74 (−1.96, 0.49) 0.238 0.788
Waist circumference (cm) −1.06 (−2.21, 0.10) 0.06 (−0.98, 1.09) −1.11 (−2.68, 0.46) 0.165 0.788
Hip circumference (cm) −1.40 (−2.35, −0.46) 0.25 (−0.61, 1.11) −1.65 (−2.95, −0.35) 0.013 0.143
Right thigh circumference (cm) 0.55 (−0.15, 1.25) 0.24 (−0.42, 0.90) 0.31 (−0.65, 1.27) 0.526 0.728
Left thigh circumference (cm) 0.66 (−0.03, 1.34) 0.35 (−0.27, 0.97) 0.31 (−0.64, 1.25) 0.523 0.788
Right arm circumference (cm) −0.39 (−0.99, 0.21) −0.28 (−0.81, 0.25) −0.11 (−0.92, 0.70) 0.788 0.788
Left arm circumference (cm) −0.34 (−0.92, 0.25) −0.20 (−0.72, 0.32) −0.14 (−0.93, 0.65) 0.733 0.788
Resting heart rate and blood pressure
Resting heart rate (beats/min) −4.21 (−6.76, −1.66) −0.45 (−2.80, 1.90) −3.76 (−7.23, −0.28) 0.034 0.306
Systolic blood pressure (mmHg) −2.04 (−4.86, 0.79) 1.78 (−0.71, 4.28) −3.82 (−7.65, 0.02) 0.051 0.459
Diastolic blood pressure (mmHg) −1.31 (−3.52, 0.90) 0.72 (−1.25, 2.70) −2.03 (−5.00, 0.93) 0.179 0.788
a p values are unadjusted for multiplicity
b p values are adjusted for multiplicity using Hommel’s [31] procedure
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recently announced a commitment to employing accredited
exercise physiologists in over 30 facilities by the end of
2018. This development will increase the accessibility of qual-
ity support and advice for men with prostate cancer who wish
to follow recommendations to be physically active.
Participation in the exercise training improved the aerobic
capacity of men with prostate cancer. Not only did the men
improve the distances walked over 6 min, but they were also
observed to have lower resting heart rates at 12 weeks, which
is a common adaption of aerobic exercise training [34]. For
the 6-min walk distance, the improvements (ADT 59.7 m,
non-ADT 47.5 m) were in excess of the recommended crite-
rion for meaningful change in older adults (20 m) and consis-
tent with the criterion for substantial meaningful change
(50 m) [35]. Given that the participants were already quite
physically active at baseline [22] and typically did not attend
all the scheduled sessions, these results may be particularly
impressive. With regard to the baseline scores for the 6-min
walk, for example, the men in this study covered more dis-
tance than men with prostate cancer in other studies [36, 37].
The men who participated in the exercise training increased
their upper and lower body strength. Given that few
randomised controlled trials focusing on these outcomes in-
cluded men not treated with ADT [38], these observations are
an important contribution to the literature. Developing and
maintaining muscle strength is imperative, because low mus-
cle strength is an independent predictor of impaired mobility
[39] and all-cause mortality [40] in older adults. Consistent
with current guidelines [11], clinicians should counsel men
with prostate cancer to include resistance exercises as part of
their training programs.
Encouraging men with prostate cancer to incorporate resis-
tance exercises as part of their training also provides opportu-
nities for their strength to be monitored (e.g. by exercise phys-
iologists or personal trainers), and for this information to be
shared with clinicians. Muscle strength is a better predictor of
morbidity and all-cause mortality than muscle mass [39, 40],
and the assessment of muscular strength is more feasible than
commonmeasures of muscle mass (e.g. via dual-energy X-ray
absorptiometry). The assessment of muscular strength could
be a valuable outcome from a referred exercise training pro-
gram, because it could be used for risk stratification and fur-
ther clinical interpretations.
The effect of the intervention on systolic blood pressure
was less pronounced and not statistically significant, but is a
finding that warrants further investigation. Previous research
on men with prostate cancer has generally shown exercise to
have no significant effect on systolic blood pressure [15–17,
41]. Control condition contamination, however, has been cited
as a possible reason for the non-significant findings in studies
of exercise and prostate cancer [41]. The magnitude of the
intervention effect (−3.82 mmHg) is slightly higher than re-
ductions achieved for adults without cardiovascular or other
diseases who participate in dynamic resistance training
(−1.8 mmHg) [42]. One reason for the muted response may
be that the resting systolic blood pressure was not high at
baseline (intervention M = 134.6, SD = 11.5, control
M=136.6, SD=11.9), with some evidence suggesting that,
for people aged over 50, systolic blood pressure
<140 mmHg should be considered normal [43]. Although
lowering systolic blood pressure when it is already
<140mmHgmay have limited health benefits (compared with
reducing systolic blood pressure to 140–160 or 140–
149 mmHg) [44], changes of the magnitude observed in the
present trial may be clinically meaningful with men who have
higher systolic blood pressure. Clinicians and researchers are
encouraged to continue investigations on the effect of exercise
training on blood pressure in men with prostate cancer.
The detrimental effect of ADTon fitness and physical func-
tioning observed previously [36, 45, 46] was also evident in
the present study. At baseline, men receiving ADT had less
strength, walked shorter distances over 6 min, and had higher
systolic blood pressure than those not treated with ADT.
Recent research has shown that declines in physical function
with ADT do not recover over a 36-month period [36], which
underscores the importance of using exercise training as a
counteractive measure.
Men treated with ADT responded to the exercise training
similarly to men who had not been treated with ADT. This
finding adds weight to the small amount of previous research
showing minimal, and statistically non-significant, differences
between men receiving ADT and those not undergoing this
treatment in terms of their responses to exercise training [18,
19]. Although some caution is appropriate when interpreting
these findings (due to the comparatively low number of men
receiving ADT recruited for the present study), it should be
noted that the differences were essentially in favour of men
receiving ADT.
A limitation of this trial was that men recruited were more
physically active than those reported in other studies [47].
Higher physical activity levels at baseline may have attenuat-
ed the magnitude of the effects that may have otherwise been
achieved through such an intervention with less active men
with prostate cancer. If the men had been less active at base-
line, clearer effects may have been observable with respect to
resting heart rate, systolic blood pressure, and waist circum-
ference. In addition, as has beenmentioned, the comparatively
small number of men receiving ADT recruited into this study
was another limitation. A larger sample of men with ADT in
this study would have enabled firmer conclusions to be drawn
about the effects of ADT on men’s responses to exercise.
Despite these limitations, the trial demonstrated that clini-
cian referral to a community-based exercise training interven-
tion with supervised and unsupervised sessions can have clear
benefits for men with prostate cancer, both in terms of their
physical function and, possibly, their cardiovascular health.
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The findings also suggest that favourable outcomes were
gained irrespective of whether or not men were treated with
ADT. These results should encourage clinicians to inform
their patients with prostate cancer about the benefits of exer-
cise and to ensure they are able to refer them to appropriately
qualified exercise practitioners or other supervised exercise
training programs to develop suitable exercise regimens for
these men.
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